Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel(nanoparticle albumin-bound paclitaxel) for the operable breast cancer (KSCOG-BC07)
Not Applicable
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000010504
- Lead Sponsor
- Department of Surgery Kurume University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Heart failure with clinically problem or history of cardiac dysfunction 2)Severe complication (uncontrolled diabetes, hypertension, renal failure, hepatic failure, Severe Infection and mental disorder which become problem on clinical practice) 3)Pregnancy and lactation or suspected pregnancy 4)Active secondary malignancy (current secondary malignancy or other malignancy within 5 years) 5)Bilateral breast cancer 6)Pulmonary fibrosis or pneumonitis 7)Allergy of the nab-Paclitaxel, Epirubicin,Cyclophosphamide and Fluorouracil 8)Physician judged improper to entry this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological complete response rate
- Secondary Outcome Measures
Name Time Method Preserving operation rate, Clinical response rate, Safety, etc.